The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
11 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $6,995,294 in first-year total cost, median $662,516.
Most frequent study sections
- Radiation Therapeutics and Biology Study Section[RTB]10
- Special Emphasis Panel[ZRG1 CTH-B (02)]1
Most frequent institutions
- BECKMAN RESEARCH INSTITUTE/CITY OF HOPE2
- DANA-FARBER CANCER INST1
- MASSACHUSETTS GENERAL HOSPITAL1
- NEW YORK UNIVERSITY SCHOOL OF MEDICINE1
- UNIVERSITY OF CALIFORNIA LOS ANGELES1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2025 | Targeting Lymphoma: A Multimodal Approach using Radiation, CART-19 Therapy, and Gut Microbiome Modulation1R01CA288473-01A1 | CHONG, ELISEFACCIABENE, ANDREAHU, BOYU | UNIVERSITY OF PENNSYLVANIA, PA | $667,533 | RTB |
| 2025 | Imaging radiation-enhanced drug delivery for safer and more effective chemoradiotherapy1R01CA291779-01A1 | MILLER, MILES A | MASSACHUSETTS GENERAL HOSPITAL, MA | $662,516 | RTB |
| 2025 | Leveraging reactive metabolite generation in brain tumors1R01CA288389-01A1 | VISWANATH, PAVITHRA | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $655,306 | RTB |
| 2025 | Drugging NRF2 to improve radiation therapy in head and neck squamous cell carcinoma1R01CA290809-01A1 | MAJOR, MICHAEL BENJAMINWEISSMAN, BERNARD E. | WASHINGTON UNIVERSITY, MO | $647,754 | RTB |
| 2024 | Enhanced radiotherapy for pediatric glioma via synthetic lethal vulnerabilities1R01CA284565-01A1 | CHOWDHURY, DIPANJANHAAS-KOGAN, DAPHNE A. | DANA-FARBER CANCER INST, MA | $767,009 | RTB |
| 2024 | Mechanisms of endocrine therapy and radiation synergism to decrease brain metastases1R01CA290813-01 | CITTELLY, DIANA M. | UNIVERSITY OF COLORADO DENVER, CO | $517,732 | ZRG1 |
| 2023 | Myeloid cell-selective, oligonucleotide-based STAT3 inhibition combined with total marrow and lymphoid irradiation for immunotherapy of acute myeloid leukemia1R01CA284593-01 | HUI, SUSANTA KKORTYLEWSKI, MARCIN | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA | $711,258 | RTB |
| 2023 | Exploiting cell fate transition to overcome radiation resistance in glioblastoma1R01CA282756-01 | BHAT, KRISHNA PLSULMAN, ERIK | NEW YORK UNIVERSITY SCHOOL OF MEDICINE, NY | $709,593 | RTB |
| 2023 | Targeted radiation and immunocytokine therapy for CEA positive malignancies1R01CA283603-01 | SHIVELY, JOHN ERNESTWONG, JEFFREY YYAZAKI, PAUL | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA | $676,263 | RTB |
| 2023 | Utilizing Radiation-Induced Multi-potency to Increase the Efficacy of Radiotherapy1R01CA281682-01 | PAJONK, FRANK | UNIVERSITY OF CALIFORNIA LOS ANGELES, CA | $507,937 | RTB |
| 2023 | PAIRS: Validating telomerase reverse transcriptase (TERT) as an intrinsic vulnerability toward sensitizing cancer to radiation1R01CA282781-01 | KRON, STEPHEN J.SCHEIDT, KARL A | UNIVERSITY OF CHICAGO, IL | $472,393 | RTB |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.